CJC-1295 5mg/vial 1 Vial by Bio-Peptide

Usage

1. Gather supplies: Bio-Peptide CJC-1295 DAC 5 mg vial, bacteriostatic water, 29–31 gauge insulin syringe, alcohol swabs, and a clean surface.
2. Wipe the rubber septum of both the peptide vial and bacteriostatic water vial with a fresh alcohol swab and allow 30 seconds to dry.
3. Draw 1–2 mL of bacteriostatic water into the insulin syringe and inject it slowly down the inner wall of the CJC-1295 DAC vial — never directly onto the lyophilized powder cake.
4. Gently swirl (do not shake) the vial until the powder fully dissolves into a clear, colourless solution; allow 1–2 minutes if needed.
5. Draw the calculated dose (e.g., 1 mg = 0.5 mL if reconstituted with 2 mL water into a 5 mg vial) and inject subcutaneously at a 45-degree angle into a clean, pinched fold of abdominal or thigh tissue; rotate sites each injection day.
6. Cap the used syringe for safe disposal, wipe the vial septum again, and store the reconstituted vial upright at 2–8 °C away from direct light — use within 28 days and discard any cloudy or particulate solution.

Warnings

Frequently asked questions

How often do you inject CJC-1295 DAC compared to other GHRH peptides?

CJC-1295 DAC is typically injected once or twice per week, which sets it apart from unmodified GHRH analogues like Modified GRF 1-29 that require multiple daily injections. The Drug Affinity Complex binds serum albumin and extends the plasma half-life to approximately 6–8 days, meaning a single subcutaneous injection sustains GHRH receptor stimulation for several days without additional dosing.

What exactly does the DAC modification do to the CJC-1295 peptide?

The DAC (Drug Affinity Complex) is a maleimidopropionic acid side chain that forms a covalent bond with cysteine-34 on serum albumin after injection. This albumin binding acts as a depot mechanism, slowly releasing active peptide into circulation over days. The result is an extended half-life of roughly 6–8 days versus 15–30 minutes for the unmodified sequence, enabling infrequent dosing while maintaining sustained GHRH receptor activity.

How much does CJC-1295 DAC raise IGF-1 levels and for how long?

In ConjuChem's Phase II clinical trial, a single 2 mg injection of CJC-1295 DAC produced a 2- to 10-fold increase in mean 24-hour GH concentrations and kept IGF-1 levels significantly elevated for at least 14 days. Individual responses vary based on baseline GH axis function, body composition, and concurrent use of GHRPs, but the two-week IGF-1 elevation per injection is the defining pharmacological feature of the DAC-modified compound.

How do you reconstitute and store a CJC-1295 DAC vial after opening?

Reconstitute the lyophilized powder by slowly injecting 1–2 mL of bacteriostatic water (preferred) or sterile water for injection along the vial wall using a standard insulin syringe — avoid shaking to prevent peptide degradation. Once reconstituted, store the vial at 2–8 °C (standard refrigerator) and use within 28 days. Never freeze a reconstituted vial, and keep it away from direct light to preserve stability.

Can CJC-1295 DAC be drawn and injected with an insulin syringe?

Yes — a 29- to 31-gauge, 0.5 mL or 1 mL insulin syringe is the standard tool for subcutaneous administration of reconstituted CJC-1295 DAC. Inject into a subcutaneous site (abdomen, outer thigh, or deltoid fat layer) at roughly a 45-degree angle. Because dosing is only once or twice weekly, rotating injection sites is straightforward and minimises local tissue irritation. (2) angle_used

Manufacturer

Bio-Peptide was founded as a specialist European peptide producer with a singular focus: applying pharmaceutical-grade synthesis standards to research-market lyophilized peptide vials at a time when purity documentation in the sector was inconsistent. The brand's founding philosophy centred on transparency — specifically, commissioning independent laboratories for both HPLC sequence verification and LAL endotoxin screening rather than relying solely on in-house quality assurance. Over successive production cycles, Bio-Peptide built its infrastructure around cGMP-aligned processes covering raw amino-acid sourcing, solid-phase peptide synthesis, lyophilization, and final vial fill, with full chain-of-custody records maintained at each stage. That institutional commitment to documented purity is what established Bio-Peptide's standing among researchers who require consistent, verifiable peptide material.